Venus Remedies Ltd Half Yearly Results

334.55
(3.53%)
Dec 6, 2024|03:31:16 PM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Financials

Particulars (Rupees in Crores.)Sept-2024Mar-2024Sept-2023Mar-2023Sept-2022

Gross Sales

276.06

338.58

262.87

272.54

282.97

Excise Duty

0

0

0

0

0

Net Sales

276.06

338.58

262.87

272.54

282.97

Other Operating Income

0

0

0

0

0

Other Income

12.17

6.27

5.31

7.09

3.23

Total Income

288.23

344.85

268.18

279.63

286.2

Total Expenditure

259.88

307.17

234.68

240

255.49

PBIDT

28.35

37.68

33.5

39.63

30.71

Interest

0.04

-0.03

0.12

-0.14

0.26

PBDT

28.31

37.71

33.38

39.77

30.45

Depreciation

12.39

12.45

13.99

15.51

16.79

Minority Interest Before NP

0

0

0

0

0

Tax

6.26

5.15

7.07

0

0

Deferred Tax

4.92

2.74

1.2

9.92

1.44

Reported Profit After Tax

4.74

17.37

11.12

14.34

12.22

Minority Interest After NP

0

0

0

0

0

Net Profit after Minority Interest

4.74

17.37

11.12

14.34

12.22

Extra-ordinary Items

0

0

0

0

0

Adjusted Profit After Extra-ordinary item

4.74

17.37

11.12

14.34

12.22

EPS (Unit Curr.)

3.54

12.99

8.32

10.73

9.14

Book Value (Unit Curr.)

0

0

0

0

0

Dividend (%)

0

0

0

0

0

Equity

13.37

13.37

13.37

13.37

13.37

Public Shareholding (Number)

0

0

0

0

0

Public Shareholding (%)

0

0

0

0

0

Pledged/Encumbered - No. of Shares

0

0

0

0

0

Pledged/Encumbered - % in Total Promoters Holding

0

0

0

0

0

Pledged/Encumbered - % in Total Equity

0

0

0

0

0

Non Encumbered - No. of Shares

0

0

0

0

0

Non Encumbered - % in Total Promoters Holding

0

0

0

0

0

Non Encumbered - % in Total Equity

0

0

0

0

0

PBIDTM(%)

10.26

11.12

12.74

14.54

10.85

PBDTM(%)

-

-

-

-

-

PATM(%)

1.71

5.13

4.23

5.26

4.31

Venus Remedies: Related NEWS

Venus Remedies gets approval for pre-filled syringe facility
6 Nov 2024|10:36 AM

Furthermore, the NPRA's recognition will enable Venus Remedies to capitalise on the expanding global demand for enoxaparin.

Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2024, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp